Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Jongen, Peter J ^a   Hengstman, Gerald ^b   Hupperts, Raymond ^c   Schrijver, Hans ^d   Gilhuis, Job ^e   Vliegen, Joseph H ^f   Hoogervorst, Erwin ^g   van Huizen, Marc ^h   van Munster, Eric ⁱ   Samijn, Johnny ^j   de Schryver, Els ^k   Siepman, Theodora ^l   Tonk, Martijn ^m   Zandbergen, Eveline ⁿ   ten Holter, Jacques ^o   van der Kruijk, Ruud ^p   Borm, George ^q  

^a MS4 Research Institute   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d Westfriesgasthuis   (Netherlands)

^e REINIER DE GRAAF HOSPITAL   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g ST ANTONIUS HOSPITAL   (Netherlands)

^h Scheper Ziekenhuis   (Netherlands)

ⁱ JEROEN BOSCH HOSPITAL   (Netherlands)

^j Maasstad Hospital Rotterdam   (Netherlands)

^k RIJNLAND HOSPITAL   (Netherlands)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ RIJNSTATE HOSPITAL   (Netherlands)

^o DEVENTER HOSPITAL   (Netherlands)

^p SLINGELAND HOSPITAL   (Netherlands)

^q RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ARTICLE; CAREGIVER; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMMUNITY CARE; DUTCH ADHERENCE QUESTIONNAIRE 90; EXPANDED DISABILITY STATUS SCALE; HEALTH CARE; HEALTH PROMOTION; HUMAN; INTERNET; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS QUALITY OF LIFE 54; MULTIPLE SCLEROSIS SELF EFFICACY SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NETHERLANDS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUALITY OF LIFE; RELAPSE; SELF CONCEPT; SELF REPORT; SOCIAL STATUS; CLINICAL TRIAL; METHODOLOGY; STATISTICS;

COHORT STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNET; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; NETHERLANDS; PEPTIDES; PROSPECTIVE STUDIES; RESEARCH DESIGN;

EID: 79953085303     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-40     Document Type: Article

References (23)

1. Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother 2006, 7(Suppl 1):1-9. 10.1517/14656566.7.1.S1, 17020427.
2. Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G, . The Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) study group Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. J Neurol 2010, 257:584-589. 10.1007/s00415-009-5378-x, 19921303, The Functional composite and quality of Life in Avonex-treated Relapsing multiple sclerosis patients (FLAIR) study group.
3. Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J, . FOCUS study group Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study. Health Qual Life Outcomes 2010, 8:133. 10.1186/1477-7525-8-133, 2999586, 21078142, FOCUS study group.
4. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP. New Natural History of Interferon-Treated Relapsing Multiple Sclerosis. Ann Neurol 2007, 61:300-306. 10.1002/ana.21102, 17444502.
5. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001, 26:331-342. 10.1046/j.1365-2710.2001.00363.x, 11679023.
6. World Health Organization. Adherence to Long-term Therapies Evidence for Action 2003, World Health Organization, Geneva, World Health Organization. Adherence to Long-term Therapies.
7. Sacket DL, Snow JC. The magnitude of compliance and non-compliance. Compliance in Health Care 1979, 11-22. Baltimore: Johns Hopkins University Press, Haynes RB, Sackett DL, Taylor DW.
8. Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med 2005, 353:487-497. 10.1056/NEJMra050100, 16079372.
9. Tremlett HL, Van der Mei I, Pittas F, Blizzard L, Paley G, Dwyer T, Taylor B, Ponsonby AL. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008, 17:565-576. 10.1002/pds.1593, 18395883.
10. Caon C, Lisak D, Penmesta R, Hreha S, Xiufang K, Tselis A, Lisak RP, Khan O. Compliance and complications after 5 years of continual therapy with interferon-beta or glatiramer acetate in relapsing-remitting multiple sclerosis. 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS: 17-20 September 2008; Montreal. Mult Scler 2008, 15(Suppl 2). Poster 25.
11. Lafata JE, Cerghet M, Dobie E, Schulz L, Tunceli K, Reuther J, Elias S. Measuring adherence and persistence to disease modifying agents among patients with relapsing remitting multiple sclerosis. J Am Pharm Assoc 2008, 48:752-757.
12. Mohr DC, Likosky W, Boudewyn AC, Marietta P, Dwyer P, Van der Wende J, Goodkin DE. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Mult Scler 1998, 4:487-489.
13. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 2003, 61:551-554.
14. Rio J, Porcel J, Tellez N, Sanchez-Betancourt A, Tintore M, Arevalo MJ, Nos C, Montalban X. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler 2005, 11:306-309. 10.1191/1352458505ms1173oa, 15957512.
15. Fraser C, Hadjimicheal O, Vollmer T. Predictors of Adherence to Copaxone Therapy in Individuals with Relapsing Remitting Multiple Sclerosis. J Neurosci Nurs 2001, 33:231-239. 10.1097/01376517-200110000-00003, 11668881.
16. Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE. Injectable Medication for the Treatment of Multiple Sclerosis: The Influence of Self-Efficacy Expectations and Injection Anxiety on Adherence and the Ability to Self-Inject. Ann Behav Med 2001, 23:125-132. 10.1207/S15324796ABM2302_7, 11394554.
17. Ross AP. Tolerability, adherence and patient outcomes. Neurology 2008, 71(Suppl 3):21-23. 10.1212/WNL.0b013e31818f3dcb, 19064871.
18. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence (Review). Cochrane Database of Systematic Reviews 2008, 3., http://www.thecochranelibrary.com
19. Ministerie van Volksgezondheid, Welzijn en Sport Dutch Medical Research Involving Human Subjects Act (WMO). International Publication Series Health, Welfare and Sport nr.2 2000, The Hague, Ministerie van Volksgezondheid, Welzijn en Sport.
20. Rigby SA, Domenech C, Thornton EW, Tedman S, Young CA. Development and validation of a self-efficacy measure for people with multiple sclerosis: the Multiple Sclerosis Self-efficacy Scale. Mult Scler 2003, 9:73-81. 10.1191/1352458503ms870oa, 12617272.
21. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Red 1995, 4:187-206.
22. Jongen PJ, Sanders E, Visser L, Zwanikken C, Peters G, van der Tol M, Koopmans P, van Noort E, . OPTIVIT Study Group Automated On-Line Monitoring of Health-Related Quality of Life and Fatigue in Relapsing Remitting Multiple Sclerosis Patients Treated with Glatiramer Acetate (Optivit Study). Neuroepidemiology 2009, 33(2):149. OPTIVIT Study Group.
23. Gehi AK, Ali S, Na B, Whooly MA. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease. Arch Intern Med 2007, 167:1798-1703. 10.1001/archinte.167.16.1798, 2789555, 17846400.